Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

AUPH Relative to the S&P 500

AUPH Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Aurinia Pharmaceuticals Inc. (NASD:AUPH) seasonal charts above shows that a Buy Date of November 23 and a Sell Date of March 22 has resulted in a geometric average return of 26.82% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 28.61% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

To download AUPH seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: AUPH